Dexcom (DXCM) stock price is $79.90, down 1.44% on the day, as of Nov 10, 2026. It has a market cap of $30.06Bn and a P/E ratio of 30.33, and is classified in the Medical Devices industry (Healthcare sector).
Enterprise Value
Margins
P/FCF
Key Stats
Market Cap30.06 Bn
P/E30.33
FCF (Yr)1.08 Bn
ROA (Yr)13.04
EV to EBIT17.88
Net Income (Yr)836.30 Mn
Enterprise Value21.88 Bn
Add ratio to table…
About
DexCom, Inc. is a medical device company focused on the design development and commercialization of continuous glucose monitoring systems for diabetes and metabolic health management. The company received FDA approval for its first product in 2006 and has since launched multiple generations of CGM systems including the G7 in 2023 and the G7 15 Day in late 2025. In August 2024 DexCom introduced Stelo the first over the counter glucose biosensor in the United States aimed at…
DexCom, Inc. is a medical device company focused on the design development and commercialization of continuous glucose monitoring systems for diabetes and metabolic health management. The company received FDA approval for its first product in 2006 and has since launched multiple generations of CGM systems including the G7 in 2023 and the G7 15 Day in late 2025. In August 2024 DexCom introduced Stelo the first over the counter glucose biosensor in the United States aimed at adults with prediabetes and type 2 diabetes who do not use insulin. DexCom operates globally with presence in North America Africa Asia Pacific Europe Latin America and the Middle East and employs approximately eleven thousand one hundred people as of December 31 2025. The company's mission is to empower people with diabetes and those seeking to optimize metabolic health to manage their glucose levels more effectively and conveniently through innovative wearable technology.
The company generates revenue primarily from the sale of continuous glucose monitoring hardware such as sensors transmitters and receivers. Associated software and services including Dexcom Share remote monitoring and data analytics also contribute to sales. Income is earned from collaborations with insulin delivery partners that integrate its CGM technology with partner devices to enable semi automated insulin delivery and data sharing. Sales of the over the counter biosensor Stelo add to revenue especially among individuals with prediabetes and type 2 diabetes who do not use insulin. DexCom uses a direct sales force in North America and selected international markets and relies on distribution arrangements in other regions to reach health care professionals and patients. Marketing efforts include direct to consumer advertising via television print digital media and participation in diabetes related events to drive awareness and adoption. The company also benefits from manufacturing facilities in Mesa Arizona Penang Malaysia and a new facility under construction in Athenry Ireland which support product supply and help meet global demand.
DexCom holds a leading position in the continuous glucose monitoring market competing primarily with Abbott Laboratories FreeStyle Libre Medtronic Guardian Connect and Simplera Roche Diabetes Care LifeScan and Ascensia Diabetes Care. The company's competitive advantages stem from high accuracy and reliability of its sensors ease of use and comfort of the wearable design strong brand recognition among patients and clinicians broad reimbursement coverage from Medicare Medicaid and private insurers and a rapid pace of innovation. DexCom benefits from its extensive patent portfolio and regulatory expertise which support timely product launches and sustained technological leadership. The firm continues to invest in research and development to expand its product pipeline and improve sensor performance algorithm accuracy and integration capabilities with digital health platforms and insulin pumps. These efforts aim to maintain its edge in a market characterized by intense competition and rapid technological change.
DexCom serves individuals with type 1 and type 2 diabetes caregivers clinicians and individuals seeking to manage metabolic health including those with prediabetes. The company also works with health care providers and payors such as Medicare Medicaid and private insurers to obtain coverage and reimbursement for its products. Its products are used by patients in home care settings and by health care professionals in clinics and hospitals across the United States and internationally. DexCom reports that its customer base includes a growing number of people with type 2 diabetes who do not use insulin but seek better glucose control through over the counter options like Stelo. The company also supports caregivers and family members through its Dexcom Share and Follow remote monitoring system which allows up to ten designated recipients to view glucose data and receive alerts. Additionally DexCom collaborates with health care organizations to provide data insights that help improve diabetes management programs and patient outcomes.
Sector:HealthcareSector rationaleDexcom is a medical device company that designs and sells continuous glucose monitoring (CGM) systems, such as the G7 and Stelo, for diabetes and metabolic health management. Its revenue is primarily derived from the sale of medical hardware (sensors, transmitters, receivers) and associated healthcare services to patients, clinicians, and healthcare providers.Industries:Medical DevicesMedical DevicesPrimaryDexcom designs and manufactures continuous glucose monitoring (CGM) systems, including the G7 and Stelo, which are wearable medical devices used for diabetes and metabolic health management. Revenue is primarily generated from the sale of this hardware, including sensors, transmitters, and receivers.Medical SuppliesMedical SuppliesSecondaryThe company sells sensors and transmitters, which are disposable medical supplies and consumables that must be replaced regularly by the patient to maintain glucose monitoring.Classified using BQ-MICSCIK: 0001093557
Bull & bear
Investment Thesis
▲ Bull case
DexCom’s strategy to expand coverage for the large type 2 non‑insulin population is creating a durable multi‑year growth runway. Management highlighted that commercial wins such as Prime Therapeutics will add more than seven million lives by year end and that CMS coverage for Medicare patients remains a matter of time. The upcoming readout of the randomized control trial at ADA 2026 is expected to provide RCT‑level evidence that could accelerate payer decisions. This structural shift in reimbursement could unlock a patient base that currently represents less than twenty five% penetration, setting the stage for sustained double‑digit revenue expansion beyond the current guidance range.
The launch of the G7 15‑day sensor is driving both new patient starts and base conversion while supporting margin improvement. Executives noted that the new algorithm delivers the highest accuracy to date and that patient feedback highlights convenience and reliability as key adoption drivers. With nearly fifty% of the installed base expected to transition to the 15‑day product by year end, the mix shift should reduce per‑sensor cost through improved yields and lower return rates. This product transition is a hidden catalyst that could lift gross margin above the current sixty three to sixty four% range if oil‑related resin pressures ease.
International markets are delivering above‑target growth and are poised to contribute increasingly to overall performance. The company reported seventeen% constant currency organic growth outside the U.S., fueled by recent access wins in France and Canada and tender successes that expand formulary presence. DexCom plans to launch Stello internationally and to bring the G7 15‑day product to additional regions, leveraging its portfolio approach to win dual formulary slots. These initiatives suggest that the international business could achieve a higher growth split than the current even‑weight assumption, providing upside to the eleven to thirteen% full‑year revenue target.
Operational excellence initiatives are translating into stronger cash flow and capital flexibility. First quarter free cash flow generation exceeded seasonal norms, pushing cash and marketable securities to approximately two billion four hundred twenty million dollars. Management emphasized that this liquidity provides capacity for tuck‑in M&A, share repurchases, and potential capital markets activity without compromising the balance sheet. The disciplined capital allocation framework discussed at the upcoming Investor Day could unlock additional shareholder value through strategic acquisitions that enhance geographic reach or add complementary sensing capabilities.
Ancillary product ecosystems are expanding the total addressable market beyond traditional diabetes care. The partnership with Signos, an FDA‑cleared AI‑powered glucose monitoring system for weight management, illustrates how DexCom’s sensor data can be monetized in adjacent consumer health verticals. DexCom’s investment in Signos and the planned distribution of Signos subscriptions via its direct‑to‑consumer site could generate recurring revenue streams that are not fully captured in the current guidance. This diversification reduces reliance on any single indications and positions the company to benefit from the growing GLP‑1 fueled weight‑loss market.
DexCom’s strategy to expand coverage for the large type 2 non‑insulin population is creating a durable multi‑year growth runway. Management highlighted that commercial wins such as Prime Therapeutics will add more than seven million lives by year end and that CMS coverage for Medicare patients remains a matter of time. The upcoming readout of the randomized control trial at ADA 2026 is expected to provide RCT‑level evidence that could accelerate payer decisions. This structural shift in reimbursement could unlock a patient base that currently represents less than twenty five% penetration, setting the stage for sustained double‑digit revenue expansion beyond the current guidance range.
The launch of the G7 15‑day sensor is driving both new patient starts and base conversion while supporting margin improvement. Executives noted that the new algorithm delivers the highest accuracy to date and that patient feedback highlights convenience and reliability as key adoption drivers. With nearly fifty% of the installed base expected to transition to the 15‑day product by year end, the mix shift should reduce per‑sensor cost through improved yields and lower return rates. This product transition is a hidden catalyst that could lift gross margin above the current sixty three to sixty four% range if oil‑related resin pressures ease.
International markets are delivering above‑target growth and are poised to contribute increasingly to overall performance. The company reported seventeen% constant currency organic growth outside the U.S., fueled by recent access wins in France and Canada and tender successes that expand formulary presence. DexCom plans to launch Stello internationally and to bring the G7 15‑day product to additional regions, leveraging its portfolio approach to win dual formulary slots. These initiatives suggest that the international business could achieve a higher growth split than the current even‑weight assumption, providing upside to the eleven to thirteen% full‑year revenue target.
Operational excellence initiatives are translating into stronger cash flow and capital flexibility. First quarter free cash flow generation exceeded seasonal norms, pushing cash and marketable securities to approximately two billion four hundred twenty million dollars. Management emphasized that this liquidity provides capacity for tuck‑in M&A, share repurchases, and potential capital markets activity without compromising the balance sheet. The disciplined capital allocation framework discussed at the upcoming Investor Day could unlock additional shareholder value through strategic acquisitions that enhance geographic reach or add complementary sensing capabilities.
Ancillary product ecosystems are expanding the total addressable market beyond traditional diabetes care. The partnership with Signos, an FDA‑cleared AI‑powered glucose monitoring system for weight management, illustrates how DexCom’s sensor data can be monetized in adjacent consumer health verticals. DexCom’s investment in Signos and the planned distribution of Signos subscriptions via its direct‑to‑consumer site could generate recurring revenue streams that are not fully captured in the current guidance. This diversification reduces reliance on any single indications and positions the company to benefit from the growing GLP‑1 fueled weight‑loss market.
The recent sensor theft incident introduces a tangible risk to brand trust and user safety that management downplayed during the call. Although DexCom identified two affected lots and issued replacement instructions, the event underscores vulnerabilities in its third‑party destruction and recycling processes. Persistent concerns about product integrity could lead to increased scrutiny from regulators, higher return rates, and potential legal liabilities that are not fully reflected in current financial guidance. This operational risk could erode the strong net promoter score gains seen with the G7 15‑day launch if not swiftly and transparently addressed.
The recent sensor theft incident introduces a tangible risk to brand trust and user safety that management downplayed during the call. Although DexCom identified two affected lots and issued replacement instructions, the event underscores vulnerabilities in its third‑party destruction and recycling processes. Persistent concerns about product integrity could lead to increased scrutiny from regulators, higher return rates, and potential legal liabilities that are not fully reflected in current financial guidance. This operational risk could erode the strong net promoter score gains seen with the G7 15‑day launch if not swiftly and transparently addressed.